Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) Receives Average Rating of “Hold” from Analysts
Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) has earned a consensus rating of “Hold” from the seven ratings firms that are covering the firm. Two analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $14.80.
Separately, Zacks Investment Research cut shares of Aegerion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, August 25th.
Shares of Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 2.57 on Wednesday. The stock’s market cap is $75.85 million. The stock’s 50 day moving average price is $2.08 and its 200-day moving average price is $2.12. Aegerion Pharmaceuticals has a 52-week low of $1.23 and a 52-week high of $16.63.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.34. Aegerion Pharmaceuticals had a negative return on equity of 128.77% and a negative net margin of 80.76%. The business had revenue of $44.50 million for the quarter, compared to analysts’ expectations of $35.50 million. On average, analysts predict that Aegerion Pharmaceuticals will post ($3.44) earnings per share for the current fiscal year.
In related news, major shareholder Healthcare Master Fun Broadfin purchased 276,000 shares of the firm’s stock in a transaction on Monday, September 12th. The shares were bought at an average price of $1.66 per share, for a total transaction of $458,160.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.60% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in AEGR. Ancora Advisors LLC bought a new position in shares of Aegerion Pharmaceuticals during the second quarter worth $114,000. Eqis Capital Management Inc. raised its position in shares of Aegerion Pharmaceuticals by 3.9% in the second quarter. Eqis Capital Management Inc. now owns 87,458 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 3,255 shares during the period. Paloma Partners Management Co bought a new position in shares of Aegerion Pharmaceuticals during the second quarter worth $142,000. Royal Bank of Canada raised its position in shares of Aegerion Pharmaceuticals by 1,193.5% in the first quarter. Royal Bank of Canada now owns 58,247 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 53,744 shares during the period. Finally, Acadian Asset Management LLC raised its position in shares of Aegerion Pharmaceuticals by 613.3% in the first quarter. Acadian Asset Management LLC now owns 110,564 shares of the biopharmaceutical company’s stock worth $410,000 after buying an additional 95,064 shares during the period. Institutional investors own 87.59% of the company’s stock.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.